Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor. It reduces the rate of thrombotic cardiovascular events, such as myocardial infarction (MI) and stroke, in patients with acute coronary syndrome (ACS).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events in patients with ACS, including patients who are managed medically and those who are managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or until a preferred duration of dual antiplatelet therapy (DAPT) is completed. In patients treated with PCI, continued treatment beyond 12 months may be considered if the benefit outweighs the increased bleeding risk.
## Pediatric Dosing
* Ticagrelor is not recommended for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* No dose adjustment is necessary based on age, sex, or renal impairment.
* **Hepatic Impairment:** No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Caution is advised in severe hepatic impairment.
## Contraindications
* **Active Bleeding:** Concomitant active pathological bleeding.
* **History of Intracranial Hemorrhage (ICH):** Prior ICH.
* **Hypersensitivity:** Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Bleeding (any site), dyspnea, bradyarrhythmias.
* **Serious:** Life-threatening bleeding, CNS bleeding, retroperitoneal bleeding, significant GI bleeding.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure and risk of bleeding. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) can decrease ticagrelor exposure and efficacy.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing exposure to substrates like simvastatin and atorvastatin. Limit doses of statins metabolized by CYP3A4 (e.g., simvastatin $\leq$ 40 mg daily, atorvastatin $\leq$ 80 mg daily).
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor closely for bleeding.
* **Proton Pump Inhibitors (PPIs):** Some data suggests potential interaction with clopidogrel via CYP2C19, but the clinical significance with ticagrelor is less clear. However, care should be taken when co-administering, as PPIs can affect gastric pH.
## Monitoring
* **Bleeding:** Closely monitor for any signs or symptoms of bleeding.
* **Heart Rate:** Monitor for bradycardia, especially in patients with pre-existing risk factors.
## Clinical Pearls
* Ticagrelor is generally preferred over clopidogrel in ACS due to faster onset of action, greater potency, and less inter-individual variability.
* Dyspnea is a common side effect, often transient and not indicative of cardiac decompensation. However, it should be evaluated to rule out other causes.
* Discontinuation of ticagrelor before completing the recommended duration of DAPT increases the risk of thrombotic events.
* Ticagrelor's reversible binding allows for quicker platelet function recovery compared to irreversible inhibitors, which may be beneficial if surgery is urgently required.
***
*This information is intended for clinical professionals. Always verify current prescribing information with the most recent FDA-approved product labeling or consult a reliable drug information resource.*
